Albany International Corp. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three months ended March 31, 2024, compared with the prior-year quarter. Albany operates through Machine Clothing (MC), which serves paper and industrial markets, and Albany Engineered Composites (AEC), which serves commercial and defense aerospace markets. The quarter includes the results of Heimbach, acquired August 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net revenues | $313.3 million | $269.1 million | 16.4% increase |
| Gross profit | $108.7 million | $99.3 million | 9.4% increase |
| Gross margin | 34.7% | 36.9% | Down 220 basis points |
| Operating income | $39.0 million | $40.5 million | 3.9% decrease |
| Operating margin | 12.4% | 15.1% | Down 270 basis points |
| Net income attributable to the Company | $27.3 million | $26.9 million | 1.5% increase |
| Diluted EPS | $0.87 | $0.86 | Increase of $0.01 |
| Operating cash flow | $9.6 million | $(16.4) million | $26.0 million improvement |
| Capital expenditures | $26.9 million | $16.3 million | Increase of $10.6 million |
Net income margin was approximately 8.7%, compared with approximately 10.1% in the prior-year quarter. The effective tax rate increased to 29.2% from 28.2%, primarily due to an unfavorable change in the forecasted jurisdictional mix of earnings. Other income was $3.0 million, compared with $0.5 million in the prior-year period, aided by foreign-currency gains and other items.
Segment performance and material changes
- Machine Clothing: Revenue increased 20.9% to $185.2 million, including $37.9 million from Heimbach. Excluding Heimbach, revenue decreased $5.3 million, primarily because of weakness in global publication grades and European markets. Segment gross margin declined to 45.7% from 50.8%, mainly due to Heimbach's lower margins; excluding Heimbach, margin increased to 52.1%. Operating income declined to $48.1 million from $49.0 million.
- AEC: Revenue increased 10.6% to $128.1 million, driven by commercial and space programs, partly offset by lower defense revenue. Gross margin increased to 18.8% from 18.5%, while operating income declined slightly to $9.2 million from $9.4 million due principally to higher technical and research costs and $2.2 million of restructuring expense.
- Consolidated SG&A increased 13.1% to $54.8 million, but declined to 17.5% of revenue from 18.0%. Technical and research expense increased 23.2% to $12.7 million, or 4.0% of revenue.
- Changes in estimated profitability of long-term contracts reduced operating income by $0.9 million, compared with a $0.7 million reduction in Q1 2023.
Liquidity, debt and cash flow
- Cash and cash equivalents were $125.4 million at March 31, 2024, down from $173.4 million at December 31, 2023. Approximately $109.0 million was held by non-U.S. subsidiaries.
- Total liquidity was approximately $496.4 million, consisting of cash and $371.0 million of available borrowings under the $800 million revolving credit facility.
- Total bank debt was $439.1 million, including $429.0 million under the revolving facility and $10.1 million of Heimbach-related foreign bank debt. Debt declined from $456.9 million at year-end 2023.
- The company was in compliance with its covenants. Its leverage ratio was 1.17x versus a maximum of 3.75x, and its interest coverage ratio was 14.38x versus a minimum of 3.00x.
- Operating cash flow was positive because of improved working-capital performance and lower tax payments. Financing cash flow was negative $28.1 million, reflecting $60.8 million of debt principal payments, $8.1 million of dividends, and $43.2 million of borrowings.
- Interest-rate swaps covering $350 million of debt expire October 27, 2024. Management expects interest costs to increase significantly thereafter as the related debt becomes subject to floating one-month SOFR-based rates.
Outlook, risks, contingencies and unusual items
- The filing does not provide quantitative full-year revenue, earnings or cash-flow guidance.
- On April 19, 2024, the company announced plans to discontinue manufacturing at its Chungju, South Korea facility and transfer production elsewhere. Estimated cash restructuring outflows are approximately $6 million, including employee costs, asset write-offs and equipment transfer costs.
- Q1 restructuring expense was $2.2 million, primarily for workforce reductions at AEC locations.
- AEC has $752 million of remaining performance obligations on contracts with original durations exceeding one year. The company expects to recognize approximately $127 million in 2024, $168 million in 2025 and $143 million in 2026.
- Key risks include aerospace production rates and program execution, customer demand and inventory levels, supply-chain and inflationary pressures, labor and material costs, foreign-currency movements, Heimbach integration, cybersecurity, government-contract funding and compliance, tax developments, and higher interest expense after the swaps expire.
- Albany was defending 3,613 asbestos claims at March 31, 2024. The company states that it cannot estimate a meaningful range of reasonably possible loss beyond accrued amounts, but expects insurance coverage of approximately $140 million to remain available and does not currently expect a material adverse effect.
- Off-balance-sheet guarantees, letters of credit and surety bonds totaled less than $12 million. No material changes to these arrangements were reported.
Important facts for investors to verify
- Whether Heimbach can improve its margins and whether integration benefits offset its added operating expenses.
- The timing and cost of the Chungju closure and other restructuring actions.
- The effect of the October 2024 swap expiration on interest expense, cash flow and covenant headroom.
- AEC commercial, defense and space program volumes, contract-margin revisions and customer concentration, including $50.1 million of Q1 sales to SAFRAN.
- Organic MC demand trends, particularly publication-grade paper and European markets.
- Progress toward converting remaining performance obligations into revenue and cash, including contract-asset balances of $179.2 million.
- Future asbestos claim activity, insurance availability and the absence of a quantifiable loss range.